Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 731-739

  Happold, Caroline ^a   Gorlia, Thierry ^b   Chinot, Olivier ^c   Gilbert, Mark R ^d   Nabors, L Burt ^e   Wick, Wolfgang ^f   Pugh, Stephanie L ^g   Hegi, Monika ^a   Cloughesy, Timothy ^h   Roth, Patrick ^a   Reardon, David A ⁱ   Perry, James R ^j   Mehta, Minesh P ^k   Stupp, Roger ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Data Management Center   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF MARYLAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVETIRACETAM; TEMOZOLOMIDE; VALPROIC ACID; ALKYLATING AGENT; ANTICONVULSIVE AGENT; DACARBAZINE; ETIRACETAM; PIRACETAM;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADOLESCENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); COMPLICATION; EPILEPSY; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; DACARBAZINE; EPILEPSY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PROGNOSIS; SURVIVAL ANALYSIS; VALPROIC ACID;

EID: 84964389314     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.6563     Document Type: Article

References (24)

1. Weller M, Gorlia T, Cairncross JG, et al: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156-1164, 2011
2. de Groot M, Reijneveld JC, Aronica E, et al: Epilepsy in patients with a brain tumour: Focal epilepsy requires focused treatment. Brain 135:1002-1016, 2012
3. van Breemen MS, Wilms EB, Vecht CJ: Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol 6:421-430, 2007
4. Weller M, Stupp R, Wick W: Epilepsy meets cancer: When, why, and what to do about it? Lancet Oncol 13:e375-e382, 2012
5. Johannessen Landmark C, Johannessen SI, Tomson T: Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev 64:896-910, 2012
6. Felix FH, Trompieri NM, de Araujo OL, et al: Potential role for valproate in the treatment of highrisk brain tumors of childhood-Results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556-570, 2011
7. Felix FH, de Araujo OL, da Trindade KM, et al: Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. J Neurooncol 116:261-266, 2014
8. Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
9. Weller M, van den Bent M, Hopkins K, et al: European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395-e403, 2014
10. Barker CA, Bishop AJ, Chang M, et al: Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86:504-509, 2013
11. Kerkhof M, Dielemans JC, van Breemen MS, et al: Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro-oncol 15:961-967, 2013
12. Oberndorfer S, Piribauer M, Marosi C, et al: P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255-260, 2005
13. Chinnaiyan P, Cerna D, Burgan WE, et al: Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410-5415, 2008
14. Chie EK, Shin JH, Kim JH, et al: In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation. Cancer Res Treat 47:527-533, 2015
15. Hosein AN, Lim YC, Day B, et al: The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol 122:263-271, 2015
16. Jaeckle KA, Ballman K, Furth A, et al: Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207-1213, 2009
17. Su JM, Li XN, Thompson P, et al: Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A children's oncology group report. Clin Cancer Res 17:589-597, 2011
18. Krauze AV, Myrehaug SD, Chang MG, et al: A Phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92:986-992, 2015
19. Kim YH, Kim T, Joo JD, et al: Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 121:2926-2932, 2015
20. Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
21. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
22. Stupp R, Hegi ME, Gorlia T, et al: European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium;CENTRIC study team: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CEN-TRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100-1108, 2014
23. Nabors LB, Fink KL, Mikkelsen T, et al: Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17:708-717, 2015
24. Bobustuc GC, Baker CH, Limaye A, et al: Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12:917-927, 2010